R. Michael Tuttle, MD

R. Michael Tuttle, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, talks about the new horizons for radioactive iodine treatment in thyroid cancer. He says some new treatments, like the MAP kinase inhibitor and BRAF inhibitor, block pathways that would allow a cancerous thyroid tumor to concentrate radioiodine.

Tuttle says there are currently research groups, such as the one at Memorial Sloan Kettering Cancer Center, that are  seeing great improvements in patients with thyroid cancer after a month of taking these inhibitors. Looking toward the future, Tuttle says he thinks the definition of how oncologists use radioactive iodine will change over the next 5 years.

Videos

R. Michael Tuttle, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, talks about the new horizons for radioactive iodine treatment in thyroid cancer.

Dr. R. Michael Tuttle on New Horizons for Radioactive Iodine Treatment

R. Michael Tuttle, MD, professor of medicine, Memorial Sloan Kettering Cancer Center, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.

This study set out to determine if data obtained during pre-operative nodule biopsy could be used to augment risk stratification.

The ensemble classifier correctly identified 72.4% (21/29) of low risk tumors and 82.6% (43/52) of intermediate/high risk tumors.

This represents another piece of information to help a physician decide on the proper approach to surgery.

Articles

R. Michael Tuttle, MD, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.


R. Michael Tuttle, MD | Authors

Articles

Dr. R. Michael Tuttle on New Horizons for Radioactive Iodine Treatment

Augmenting Pre-Operative Risk of Recurrence Stratification in DTC